Literature DB >> 8662837

Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFalpha, but the dimer is a more potent TNF inhibitor.

M Schreiber1, K Rajarathnam, G McFadden.   

Abstract

The myxoma virus T2 (M-T2) gene expresses a secreted protein that contains significant sequence similarity to the ligand binding domains of the cellular tumor necrosis factor (TNF) receptors, specifically inhibits the cytolytic activity of rabbit TNFalpha and is an important virulence factor for myxoma virus infection in rabbits. M-T2 protein was overexpressed from vaccinia virus vectors, purified to apparent homogeneity, and found to specifically protect mouse and rabbit cells from lysis by rabbit TNFalpha at molar ratios comparable with the soluble versions of the host tumor necrosis factor receptors. M-T2 secreted from virus-infected cells is detected as both a monomer and a disulfide-linked dimer, both of which were shown by Scatchard analysis to bind rabbit TNFalpha (Kd values of 170 pM and 195 pM, respectively), values that are comparable with the affinities of mammalian TNFs with their receptors. In contrast to the rabbit ligand, M-T2 interacts with mouse TNFalpha with a much lower affinity, Kd of 1.7 nM, and was unable to inhibit the cytolytic activity of this ligand on mouse cells. Although both monomeric and dimeric forms bound rabbit TNFalpha with comparable affinity, the dimeric M-T2 protein was a far more potent inhibitor of rabbit TNFalpha, presumably because it can more effectively prevent dimerization of TNF receptors than can the M-T2 monomer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662837     DOI: 10.1074/jbc.271.23.13333

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Authors:  Lisa M Sedger; Sarah R Osvath; Xiao-Ming Xu; Grace Li; Francis K-M Chan; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function.

Authors:  Victoria M Wahl-Jensen; Tatiana A Afanasieva; Jochen Seebach; Ute Ströher; Heinz Feldmann; Hans-Joachim Schnittler
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition.

Authors:  M Schreiber; L Sedger; G McFadden
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines.

Authors:  A S Lalani; K Graham; K Mossman; K Rajarathnam; I Clark-Lewis; D Kelvin; G McFadden
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Post-translational modification of the myxoma-virus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase.

Authors:  P Nash; M Barry; B T Seet; K Veugelers; S Hota; J Heger; C Hodgkinson; K Graham; R J Jackson; G McFadden
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

6.  Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore.

Authors:  S T Wasilenko; A F Meyers; K Vander Helm; M Barry
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Genetic Variability of Myxoma Virus Genomes.

Authors:  Christoph Braun; Andrea Thürmer; Rolf Daniel; Anne-Kathrin Schultz; Ingo Bulla; Horst Schirrmeier; Dietmar Mayer; Andreas Neubert; Claus-Peter Czerny
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 8.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

9.  A third distinct tumor necrosis factor receptor of orthopoxviruses.

Authors:  V N Loparev; J M Parsons; J C Knight; J F Panus; C A Ray; R M Buller; D J Pickup; J J Esposito
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

10.  A unique bivalent binding and inhibition mechanism by the yatapoxvirus interleukin 18 binding protein.

Authors:  Brian Krumm; Xiangzhi Meng; Zhixin Wang; Yan Xiang; Junpeng Deng
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.